Study S000764

A Randomised, Double-blind, Single-centre, Three-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Each of the Two New Liraglutide Formulations at pH 7.9 and 8.15 and the Planned Phase 3 Formulation at pH 7.7

ClinicalTrials.gov record

Registration

Registration: NCT01514487
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 24
Start: 2005-01-13
Primary completion: 2005-03-30
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Healthy
Interventions: DRUG:liraglutide
Results posted: FALSE

Registered primary outcomes

Area under the Curve (0-t) []
Cmax, maximum concentration []

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.